Angela Braly - Procter Gamble Independent Director
PG Stock | USD 161.29 0.00 0.00% |
Director
Ms. Angela F. Braly is an Independent Director of the Company. Ms. Braly is the former Chair of the Board, President and Chief Executive Officer of WellPoint, Inc., now known as Anthem, Inc. She served as Chair of the Board from 2010 to 2012 and as President and Chief Executive Officer from 2007 to 2012. She previously served as Executive Vice President, General Counsel, and Chief Public Affairs Officer of WellPoint from 2005 to 2007, and President and Chief Executive Officer of Blue Cross Blue Shield of Missouri from 2003 to 2005. Ms. Braly was a Director of Lowes Companies, Inc. since 2013, Brookfield Asset Management since 2015, and ExxonMobil Corporation since 2016. Ms. Bralys diverse Leadership, Strategy, and Risk Management experience at WellPoint enables her to provide valuable insight about risk management and governance matters, particularly as it pertains to the Consumer IndustryRetail sector, to the Board. Additionally, her role as General Counsel and Chief Public Affairs Officer for WellPoint, where she was responsible for the companys government relations, public policy development, social responsibility, and corporate governance initiatives, and her experience on other public company boards enables her to bring significant Corporationrationrate Governance expertise and GovernmentRegulatory skills to the Board, which is critical during current times of political and economic uncertainty. since 2009.
Age | 59 |
Tenure | 15 years |
Address | One Procter & Gamble Plaza, Cincinnati, OH, United States, 45202 |
Phone | 513 983 1100 |
Web | https://www.pginvestor.com |
Procter Gamble Management Efficiency
The company has Return on Asset (ROA) of 0.1116 % which means that for every $100 of assets, it generated a profit of $0.1116. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.3179 %, which means that it produced $0.3179 on every 100 dollars invested by current stockholders. Procter Gamble's management efficiency ratios could be used to measure how well Procter Gamble manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.14. The current Return On Capital Employed is estimated to decrease to 0.20. At this time, Procter Gamble's Other Assets are most likely to increase significantly in the upcoming years. The Procter Gamble's current Asset Turnover is estimated to increase to 0.99, while Non Current Assets Total are projected to decrease to roughly 65.5 B.Similar Executives
Showing other executives | DIRECTOR Age | ||
Carlos Represas | Merck Company | 72 | |
Pamela Craig | Merck Company | 64 | |
Maryscott Greenwood | Tilray Inc | 51 | |
Michael Auerbach | Tilray Inc | 41 | |
Rochelle Lazarus | Merck Company | 71 | |
Christine Seidman | Merck Company | 68 | |
Mary Coe | Merck Company | 54 | |
John Noseworthy | Merck Company | 66 | |
Leslie Brun | Merck Company | 68 | |
Rebekah Dopp | Tilray Inc | 40 | |
Christine Clare | Tilray Inc | 66 | |
Inge Thulin | Merck Company | 67 | |
ron Sugar | Air Lease | 66 | |
Paul Rothman | Merck Company | 63 | |
Patricia Russo | Merck Company | 68 | |
Mary DePalma | Air Lease | N/A | |
Wendell Weeks | Merck Company | 59 | |
Cheryl Krongard | Air Lease | 65 | |
Thomas Cech | Merck Company | 72 | |
Kathy Warden | Merck Company | 49 | |
Robert Kidder | Merck Company | 71 |
Management Performance
Return On Equity | 0.32 | ||||
Return On Asset | 0.11 |
Procter Gamble Leadership Team
Elected by the shareholders, the Procter Gamble's board of directors comprises two types of representatives: Procter Gamble inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Procter. The board's role is to monitor Procter Gamble's management team and ensure that shareholders' interests are well served. Procter Gamble's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Procter Gamble's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kathleen Fish, Chief Research, Development and Innovation Officer | ||
Craig Buchholz, Chief Communications Officer and Vice President – Communications, Personal Health Care and Oral Care | ||
Matthew Janzaruk, Senior Officer | ||
Mary FergusonMcHugh, Group President - Global Family Care and Global Brand Creation and Innovation, P&G Ventures | ||
Kenneth Chenault, Independent Director | ||
Debra Lee, Independent Director | ||
Mindy Sherwood, President Global Walmart | ||
Amy Chang, Independent Director | ||
Nelson Peltz, Independent Director | ||
Martin Riant, Group Pres and Advisor to the CEO | ||
Hatsunori Kiriyama, President - Asia | ||
Magesvaran Suranjan, President - Asia Pacific Selling and Market Operations | ||
Kirti Singh, Chief Analytics and Insights Officer | ||
Tarek Farahat, President - Latin America | ||
Francis Blake, Independent Director | ||
Thomas Finn, President - Personal Health Care | ||
Mohamed Samir, President - India, Middle East and Africa (IMEA) Selling and Market Operations | ||
Alexandra Keith, President - Global Hair Care and Beauty Sector | ||
Susan DesmondHellmann, Independent Director | ||
Valarie Sheppard, Controller and Treasurer and Executive Vice President - Company Transition Leader | ||
Fama Francisco, Chief Executive Officer - Baby and Feminine Care | ||
Loic Tassel, President - Europe | ||
Margaret Whitman, Independent Director | ||
Walter McNerney, Lead Independent Director | ||
Terry Lundgren, Independent Director | ||
Shelly McNamara, Senior Vice President of Human Resources | ||
Angela Braly, Independent Director | ||
Giovanni Ciserani, Group President of Global Fabric and Home Care and Global Baby and Feminine Care | ||
M Grabowski, Chief Human Resource Officer | ||
Victor Aguilar, Chief Research, Development and Innovation Officer | ||
Damon Jones, Chief Officer | ||
Javier Polit, Chief Information Officer | ||
B Allen, Independent Director | ||
James McNerney, Lead Independent Director | ||
Ernesto Zedillo, Independent Director | ||
Steven Bishop, Group President - Global Feminine and Family Care | ||
Scott Cook, Independent Director | ||
Henry Karamanoukian, President Go-to-Market, China and Hair Care, Greater China | ||
Sundar Raman, President - Fabric Care, North America and P&G Professional, Global | ||
Ernesto Leon, Independent Director | ||
Susan Whaley, Chief Secretary | ||
R Keith, President - Global Hair Care and Beauty Sector | ||
Ma Francisco, Chief Executive Officer - Baby and Feminine Care | ||
Yannis Skoufalos, Global Product Supply Officer | ||
Linda ClementHolmes, CIO | ||
Jennifer Davis, President - Feminine Care | ||
John Chevalier, Director - Investor Relations | ||
Juan Posada, President - Latin America Selling and Market Operations | ||
Fatima Francisco, Feminine Baby | ||
Alan Lafley, Executive Chairman and Member of Proxy Committee | ||
Jeffrey Schomburger, Global Sales Officer | ||
Monica Turner, Senior Vice President - Sales, North America | ||
Vittorio Cretella, Chief Information Officer | ||
Christine McCarthy, Independent Director | ||
Patricia Woertz, Independent Director | ||
Shailesh Jejurikar, Chief Operating Officer, Chief Executive Officer - Fabric and Home Care | ||
Philip Duncan, Chief Design Officer | ||
Andre Schulten, Chief Financial Officer | ||
Marc Pritchard, Global Brand Building Officer | ||
Markus Strobel, President - Skin & Personal Care | ||
David Taylor, Chairman of the Board, President, Chief Executive Officer | ||
Mark Biegger, Global Human Resources Officer | ||
Joseph Jimenez, Lead Independent Director | ||
Matthew Price, President - Greater China Selling and Market Operations | ||
Julio Nemeth, President - Global Business Services | ||
Laura Becker, President - Global Business Services | ||
Deborah Majoras, Chief Legal Officer, Secretary | ||
Jon Moeller, Vice Chairman of the Board, President, Chief Executive Officer | ||
Patrice Louvet, Group President - Global Beauty | ||
Charles Pierce, Group President - Global Grooming | ||
Gary Coombe, President - Europe Selling and Market Operations | ||
Carolyn Tastad, Group President - North America Selling and Market Operations | ||
Ken Patel, Chief Counsel |
Procter Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Procter Gamble a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.32 | ||||
Return On Asset | 0.11 | ||||
Profit Margin | 0.18 % | ||||
Operating Margin | 0.23 % | ||||
Current Valuation | 406.9 B | ||||
Shares Outstanding | 2.36 B | ||||
Shares Owned By Insiders | 0.09 % | ||||
Shares Owned By Institutions | 67.30 % | ||||
Number Of Shares Shorted | 14.99 M | ||||
Price To Earning | 25.21 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Procter Gamble using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Procter Gamble. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more detail on how to invest in Procter Stock please use our How to Invest in Procter Gamble guide.Note that the Procter Gamble information on this page should be used as a complementary analysis to other Procter Gamble's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Procter Stock analysis
When running Procter Gamble's price analysis, check to measure Procter Gamble's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procter Gamble is operating at the current time. Most of Procter Gamble's value examination focuses on studying past and present price action to predict the probability of Procter Gamble's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procter Gamble's price. Additionally, you may evaluate how the addition of Procter Gamble to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Procter Gamble's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Procter Gamble. If investors know Procter will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Procter Gamble listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.106 | Dividend Share 3.763 | Earnings Share 6.11 | Revenue Per Share 35.616 | Quarterly Revenue Growth 0.006 |
The market value of Procter Gamble is measured differently than its book value, which is the value of Procter that is recorded on the company's balance sheet. Investors also form their own opinion of Procter Gamble's value that differs from its market value or its book value, called intrinsic value, which is Procter Gamble's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Procter Gamble's market value can be influenced by many factors that don't directly affect Procter Gamble's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Procter Gamble's value and its price as these two are different measures arrived at by different means. Investors typically determine if Procter Gamble is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Procter Gamble's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.